Quantcast
Home > Quotes > ENTA
x
ENTA

Enanta Pharmaceuticals, Inc. Common Stock (ENTA) Quote & Summary Data

$76.12
*  
1.43
1.91%
Get ENTA Alerts
*Delayed - data as of Oct. 15, 2018  -  Find a broker to begin trading ENTA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ENTA After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 24.44 / $ 90
1 Year Target
100
Today's High / Low
$ 77.55 / $ 73.74
Share Volume
166,786
50 Day Avg. Daily Volume
270,311
Previous Close
$ 74.69
52 Week High / Low
$ 127.77 / $ 44.52
Market Cap
1,475,017,355
P/E Ratio
18.89
Forward P/E (1y)
20.98
Earnings Per Share (EPS)
$ 4.03
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.04

Intraday Chart

Shares Traded

Share Volume:
166,786
50 Day Avg. Daily Volume:
270,311

P/E Ratio

P/E Ratio:
18.89
Forward P/E (1y):
20.98
Earnings Per Share (EPS):
$ 4.03

Trading Range

The current last sale of $76.12 is 70.98% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 77.55 $ 127.77
 Low: $ 73.74 $ 44.52

ETFs with ENTA as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.6% Invesco Dynamic Biotech & Genome ETF (PBE) +3.03 (5.98%)
0.61% IQ Chaikin U.S. Small Cap ETF (CSML) -2.60 (-9.13%)
0% Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) +4.36 (17.01%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to create small molecule drugs primarily for the treatment of viral infections and liver diseases. We discovered glecaprevir, the second of two protease inhibitors discovered and developed through our collaboration with AbbVie and marketed as part of AbbVie's new direct-acting antiviral (DAA) regimen under the tradenames MAVYRET(TM) (U.S.) or MAVIRET(TM) (ex-U.S.) (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis C virus, or HCV. The other protease inhibitor under our HCV collaboration is part of AbbVie's initial DAA regimens for the treatment of chronic HCV marketed under the tradenames VIEKIRA PAK┬« (paritaprevir/ritonavir/ombitasvir /dasabuvir) (U.S.) or VIEKIRAX┬« (paritaprevir/ritonavir/ombitasvir) (ex-U.S.).  ... More ...  


Risk Grade

Where does ENTA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 74.57
Open Date:
Oct. 15, 2018
Close Price:
$ 76.12
Close Date:
Oct. 15, 2018

Consensus Recommendation

Analyst Info